Skip to main navigation Skip to search Skip to main content

A likelihood ratio approach for utilizing case-control data in the clinical classification of rare sequence variants: application to BRCA1 and BRCA2.

  • GC-HBOC Study Collaborators
  • The Cyprus Institute of Neurology and Genetics
  • QIMR Berghofer Medical Research Institute
  • University of Utah
  • University of Cambridge
  • University of Helsinki
  • Lunenfeld-Tanenbaum Research Institute
  • University of California, Irvine
  • Queen's University Belfast
  • Lund University
  • University Medical Center Hamburg-Eppendorf
  • Copenhagen University Hospital
  • DKFZ (Deutsches Krebsforschungszentrum Heidelberg)
  • University of Queensland
  • Institut Curie
  • Instituto de Investigación Sanitaria Galicia
  • Karolinska Institutet
  • Fox Chase Cancer Centre
  • IRCCS San Raffaele Scientific Institute
  • Leiden University Medical Center
  • Medizinische Hochschule Hannover (Hannover Medical School)
  • University of Westminster
  • University of Southampton
  • Universitat Leipzig
  • University Hospital Erlangen
  • Complejo Hospitalario Universitario de Santiago
  • National Cancer Institute
  • Hospital Clinico San Carlos
  • Ramsay Memorial Fellowship Trust
  • Erasmus MC
  • Monash University
  • McGill University
  • Maastricht University Medical Center
  • Université Paris-Saclay
  • Universitat zu Koln University of Cologne
  • University of Southern California
  • Netherlands Cancer Institute

Research output: Contribution to journal › Article › peer-review

Abstract

A large number of variants identified through clinical genetic testing in disease susceptibility genes are of uncertain significance (VUS). Following the recommendations of the American College of Medical Genetics and Genomics (ACMG) and Association for Molecular Pathology (AMP), the frequency in case-control datasets (PS4 criterion) can inform their interpretation. We present a novel case-control likelihood ratio-based method that incorporates gene-specific age-related penetrance. We demonstrate the utility of this method in the analysis of simulated and real datasets. In the analysis of simulated data, the likelihood ratio method was more powerful compared to other methods. Likelihood ratios were calculated for a case-control dataset of BRCA1 and BRCA2 variants from the Breast Cancer Association Consortium (BCAC) and compared with logistic regression results. A larger number of variants reached evidence in favor of pathogenicity, and a substantial number of variants had evidence against pathogenicity findings that would not have been reached using other case-control analysis methods. Our novel method provides greater power to classify rare variants compared with classical case-control methods. As an initiative from the ENIGMA Analytical Working Group, we provide user-friendly scripts and preformatted Excel calculators for implementation of the method for rare variants in BRCA1, BRCA2, and other high-risk genes with known penetrance.

Original languageEnglish
Article number9961341
JournalHuman Mutation
Volume2023
DOIs
Publication statusPublished - 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Humans
  • Case-Control Studies
  • BRCA2 Protein/genetics
  • Genetic Predisposition to Disease
  • Female
  • BRCA1 Protein/genetics
  • Breast Neoplasms/genetics
  • Likelihood Functions
  • Genetic Variation
  • Penetrance
  • Genetic Testing/methods

Fingerprint

Dive into the research topics of 'A likelihood ratio approach for utilizing case-control data in the clinical classification of rare sequence variants: application to BRCA1 and BRCA2.'. Together they form a unique fingerprint.

Cite this